文献速递肺栓塞与肺血管病

肺动脉高压中的神经激素调节

Neurohormonal modulation in pulmonary arterial hypertension.
PubMed 文献 · Eur Respir J · 2021-10-28

本文综述肺动脉高压(PAH)中神经激素失衡与不良预后相关,并总结已在前临床和临床测试的药物与非药物神经激素调节策略。作者指出获益受限于对疾病全程神经激素变化认识不足及动物到人体转化困难,提出需纵向个体化评估神经激素状态,PET等影像技术可能有助于确定疾病阶段和优化个体治疗反应。

要点

  • PAH患者神经激素失衡与更差预后和生存相关。
  • 神经激素调节策略的临床获益受限于疾病全程神经激素变化认识不足及动物到人体转化困难。
  • 建议纵向和个体化评估神经激素状态以改善调节时机和特异性,PET等影像技术可能有助于确定疾病阶段和优化个体治疗反应。

核心结论

  • PAH患者神经激素失衡与更差预后和生存相关。
  • 神经激素调节策略的获益受限于对疾病全程神经激素变化认识不足及动物模型到人体试验转化困难。
  • 需纵向和个体化评估神经激素状态以改善调节时机和特异性。

研究设计与样本

  • 本文为关于PAH神经激素调节的基础综述,概述已在前临床和临床测试的药物与非药物策略。

主要发现

  • PAH以较小肺血管进行性重构和阻塞为特征。
  • PAH患者神经激素失衡与更差预后和生存相关。

临床怎么用

  • 建议纵向和个体化评估PAH患者神经激素状态以改善神经激素调节策略的时机和特异性。
  • PET等影像技术进展可能有助于确定不同疾病阶段的神经激素状态并优化个体治疗反应。

局限性

  • 对神经激素系统在疾病全程中如何变化认识不足。
  • 动物模型到人体试验转化困难。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pulmonary hypertension is a fatal condition of elevated pulmonary pressures, complicated by right heart failure. Pulmonary hypertension appears in various forms; one of those is pulmonary arterial hypertension (PAH) and is particularly characterised by progressive remodelling and obstruction of the smaller pulmonary vessels. Neurohormonal imbalance in PAH patients is associated with worse prognosis and survival. In this back-to-basics article on neurohormonal modulation in PAH, we provide an overview of the pharmacological and nonpharmacological strategies that have been tested pre-clinically and clinically. The benefit of neurohormonal modulation strategies in PAH patients has been limited by lack of insight into how the neurohormonal system is changed throughout the disease and difficulties in translation from animal models to human trials. We propose that longitudinal and individual assessments of neurohormonal status are required to improve the timing and specificity of neurohormonal modulation strategies. Ongoing developments in imaging techniques such as positron emission tomography may become helpful to determine neurohormonal status in PAH patients in different disease stages and optimise individual treatment responses.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Peters EL, Bogaard HJ, Vonk Noordegraaf A, et al. Neurohormonal modulation in pulmonary arterial hypertension. Eur Respir J. 2021. PMID: 33766951. doi:10.1183/13993003.04633-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。